Pharming Group

Unternehmensprofil

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Beschreibung auf Englisch verfügbar.

Unternehmensdaten

Branche

Gesundheit

Industrie

Biotechnology

Land

Niederlande

Hauptsitz

Darwinweg 24, 2333 CR, Leiden

Mitarbeitende

407

Notierung

PHARM · Euronext Amsterdam

Währung

EUR

ISIN

NL0010391025

Website

pharming.com